Nascent Biotech Inc. · OTC:NBIO
Nascent Biotech — Investor Presentation (October 2019)
18 slides from Nascent Biotech's investor presentation, October 2019
Slide 1: Corporate Overview
NBIO:OTCQB Corporate Overview Non-Confidential Information October 2019
Slide 2: Safe Harbor for Forward-Looking Statements
Safe Harbor for Forward-Looking Statements This presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which
Slide 3: Contents
Contents • Overview – Nascent Biotech and Development Pipeline • Therapeutic Target and Unmet Need • Pritumumab – Non-Clinical Data • Capital Requirements • Near-Term Development and Operations • Investment Summary • Leadership Team • Next Steps 3
Slide 4: Overview -- Nascent Biotech and Pritumumab
Overview -- Nascent Biotech and Pritumumab Founded - A Nevada public company (NBIO:OTCQB); headquartered in San Diego, CA - Formed in 2014 to continue development of Pritumumab, a fully human IgG monoclonal antibody, to treat epithelial cancers. • Founder: Mark Glassy, Ph.D. (UCSD; Scripps Clinic an
Slide 5: Nascent Biotech Development Pipeline
Nascent Biotech Development Pipeline Patient-derived Monoclonal PROGRAM NONCLIN R&D PHASE 1 PHASE 2 PARTNER Antibody Brain cancer U.S. (2020) China Pancreatic U.S. cancer* Gynecologic* U.S. * Market Expansion to pancreatic and gynecologic cancers in 2021 5 non-confidential
Slide 6: Brain Cancer and Pancreatic Cancer represent a significant Unmet Need
Brain Cancer and Pancreatic Cancer represent a significant Unmet Need Brain Cancer • 1-year & 5-year survival rates for current 1st-line therapeutic strategies (surgery, TEMODAR®) are: • 60% and 35%, respectively, for all brain cancers • 36% and 5%, respectively, for glioblastomas – SEER Registry Da
Slide 7: Pritumumab Targets Cancer-Associated Vimentin
Pritumumab Targets Cancer-Associated Vimentin Pritumumab 7 non-confidential
Slide 8: Non-Clinical Development of Pritumumab in U.S.
Non-Clinical Development of Pritumumab in U.S. Including IND-Enabling Studies & IND Submission 8 non-confidential
Slide 9: Summary Of Non-Clinical Development in the U.S.
Summary Of Non-Clinical Development in the U.S. ü Fully human recombinant monoclonal antibody (mAb) produced in the novel CHO expression system at Catalent ü Exploratory and IND-enabling studies completed in U.S. - Revalidation: mAb specifically recognizes cell surface Vimentin - Binding to the reco
Slide 10: Hybridoma-derived Pritumumab Compared to CHO Cell Line Pritumumab
Hybridoma-derived Pritumumab Compared to Pritumumab produced in Chinese Hamster Ovary (CHO) Cell Line The original Pritumumab studied previously was Hybridoma-derived. Nascent has reformulated Pritumumab to be expressed in CHO cells. Human Hybridoma- GPEx CHO Comparison derived mAb Pritumumab The bi
Slide 11: Imaging Of Brain Cancer with 89Zr-labeled Pritumumab
Imaging Of Brain Cancer with 89Zr-labeled Pritumumab Imaging studies show preferential tumor uptake of Pritumumab PET/CT slices and maximum intensity projections Schema for DFO chelator conjugation to PRIT and Autoradiography subsequent radiolabeling of antibody with Zr-89 - Dr. Pillarsetty (MSKCC)
Slide 12: Imaging Of Brain Cancer with 89Zr-labeled Pritumumab
Imaging Of Brain Cancer with 89Zr-labeled Pritumumab Subcutaneous Tumor Model - U251 GBM Cell Line Biodistribution - Dr. Pillarsetty (MSKCC) & Nascent Biotech Representative images displaying transaxial and coronal PET slices (top) and maximum intensity projections (bottom) of a mouse bearing subcut
Slide 13: Imaging Of Brain Cancer with Cy5.5-labeled Pritumumab
Imaging Of Brain Cancer with Cy5.5-labeled Pritumumab Pritumumab accumulates at the tumor site and is retained for a sustained period C6 Orthotopic Brain Tumors U87 Orthotopic Brain Tumors - Hisun Pharma, University of Peking & Nascent Biotech 13 non-confidential
Slide 14: Capital Investment - Timeline and Budget
Capital Investment - Timeline and Budget -- Initiation of Brain Cancer Phase 1 Trial -- File IND for Pancreatic Cancer -- Fund Ongoing Company Operations through 2021 14 non-confidential
Slide 15: $11.55M Capital Investment
$11.55M Capital Investment Initiate Clinical Trials, Achieve Near-term Milestones, Finance Operations Phase I/II trial – Gliomas Phase I/II trial File and Approval of 2nd IND Pancreatic CA 2019 2020 2021 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 First Clinical Results from FPI Finalize IND Submit FPI Glio
Slide 16: Nascent Biotech Inc. - Investment Highlights
Nascent Biotech Inc. - Investment Highlights A Growing Biotechnology Company Developing First-in-class Monoclonal Antibody Therapies to Treat Orphan Oncology Indications Having Significant Unmet Need Derisked Opportunity: Pritumumab: a fully Human Monoclonal Antibody - IND-approved in U.S. for patie
Slide 17: Leadership Team Focused On Execution
Leadership Team Focused On Execution Prior Experience Sean Carrick President, Chief Executive Officer Brandon Price, Ph.D. Executive VP, Business Development Lowell Holden Chief Financial Officer Douglas Karas Board of Directors Mark Glassy, Ph.D. Founder; Chairman - Scientific Advisory Board 17 non
Slide 18: Contact
Sean Carrick, CEO sean.carrick@nascentbiotech.com Barrett S. McGrath Corporate Development barrett.mcgrath@nascentbiotech.com 6330 Nancy Ridge Dr Suite 105 San Diego, CA 92121 (772) 713-0541 18
Nascent Biotech — Investor Presentation (October 2019) on 6ix